| Literature DB >> 16859535 |
Devesh Mewar1, Annabel Coote, David J Moore, Ioanna Marinou, Jodie Keyworth, Marion C Dickson, Doug S Montgomery, Michael H Binks, Anthony G Wilson.
Abstract
Several recent publications have established a strong association between anti-cyclic citrullinated peptide antibody (anti-CCP)-positive rheumatoid arthritis (RA) and carriage of shared epitope (SE) alleles. Although anti-CCP have also been associated with more severe RA, the issue of whether this is independent of rheumatoid factor (RF) has not been addressed. To identify associations between RF, anti-CCP, SE status and radiological damage, we studied a large cross-sectional cohort with longstanding RA. Individuals (n = 872) enrolled in the study all fulfilled the American College of Rheumatology criteria for RA, had a minimum disease duration of 3 years, and at least one definite radiographic erosion was present in hands or feet. Radiographs were scored blind at study entry by a single musculoskeletal radiologist using a modified Larsen's score. Anti-CCP and RF levels were determined using enzyme-linked immunosorbent assay, and DRB1 typing was performed using polymerase chain reaction based methodology. Both anti-CCP and RF levels were strongly associated with radiographic severity (P < 0.0001). In subgroups stratified for both anti-CCP and RF status, evidence of independent associations of both antibodies with radiographic outcome was found (P < 0.0001). An association of SE alleles with radiographic severity was present only in RF-negative individuals. Anti-CCP positivity was associated with SE status with evidence of a gene-dose effect, most markedly in RF-negative individuals (P < 0.01). Anti-CCP and RF status are independent severity factors for RA, with SE alleles playing at most a secondary role. Our data support the view that previously described associations between SE and radiological severity, especially in RF-negative patients, may be indirect and due to an association with anti-CCP.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16859535 PMCID: PMC1779371 DOI: 10.1186/ar2017
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Radiographic damage in patients stratified for RF and anti-CCP status
| Antibody status | Larsen's score (mean ± SEM) | ||
| RF positive | 552 | 49.1 ± 1.7 | <0.0001a |
| RF negative | 268 | 33.0 ± 1.9 | |
| Anti-CCP positive | 672 | 46.9 ± 1.5 | <0.0001a |
| Anti-CCP negative | 159 | 31.3 ± 2.4 | |
| RF positive/CCP positive | 493 | 49.6 ± 1.8 | <0.0001b |
| RF positive/CCP negative | 39 | 37.6 ± 5.2 | |
| RF negative/CCP positive | 143 | 37.2 ± 2.7 | |
| RF negative/CCP negative | 109 | 28.0 ± 2.8 |
Shown is an analysis of radiographic damage, as assessed by modified Larsen's score, in patients stratified for RF and anti-CCP status. at-test. bComparison of four groups by analysis of variance. anti-CCP, anti-cyclic citrullinated peptide antibody; RF, rheumatoid factor; SEM, standard error of the mean.
Radiographic damage among patients with two, one, or no copies of SE alleles stratified according to RF and anti-CCP status
| Antibody status | Number of SE alleles | Larsen's score (mean ± SEM) | ||
| All | 2 | 266 | 46.5 ± 2.3 | NS |
| 1 | 393 | 43.6 ± 1.9 | ||
| 0 | 168 | 39.2 ± 2.6 | ||
| RF positive | 2 | 177 | 49.5 ± 2.9 | NS |
| 1 | 253 | 49.4 ± 2.5 | ||
| 0 | 94 | 47.0 ± 3.7 | ||
| RF negative | 2 | 71 | 39.0 ± 4.3 | 0.0458a |
| 1 | 120 | 32.3 ± 2.7 | ||
| 0 | 65 | 25.9 ± 3.1 | ||
| CCP positive | 2 | 226 | 49.1 ± 2.5 | NS |
| 1 | 312 | 45.7 ± 2.1 | ||
| 0 | 98 | 44.3 ± 3.4 | ||
| CCP negative | 2 | 30 | 32.0 ± 5.9 | NS |
| 1 | 67 | 32.3 ± 3.7 | ||
| 0 | 58 | 29.2 ± 3.9 |
Shown is an analysis of radiographic damage among patients with 2 (SE2), 1 (SE1) or no (SE0) copies of SE alleles stratified according to RF and anti-CCP (shortened to CCP) status. aBy analysis of variance. anti-CCP, anti-cyclic citrullinated peptide antibody; NS, not significant; RF, rheumatoid factor; SEM, standard error of the mean.
Association between SE alleles and anti-CCP status
| RF status | Number of SE alleles | Proportion anti-CCP positive | OR (95% CI) | |
| All | 2 | 214/241 | 4.94 (2.94–8.22) | <0.001 |
| 1 | 307/373 | 2.90 (1.89–4.43) | ||
| 0 | 98/159 | 1 | ||
| RF positive | 2 | 162/170 | 4.15 (1.79–9.58) | <0.01 |
| 1 | 236/253 | 2.85 (1.41–5.77) | ||
| 0 | 78/94 | 1 | ||
| RF negative | 2 | 52/71 | 6.16 (3.00–12.6) | <0.001 |
| 1 | 71/120 | 3.26 (1.74–6.11) | ||
| 0 | 20/65 | 1 |
Absolute numbers of anti-CCP-positive patients in each subgroup are given. OR with 95% CI are shown for anti-CCP positivity associated with carriage of two or one SE allele versus no SE alleles for RF positive, RF negative and combined subgroups. P values are for χ2 tests with two degrees of freedom comparing the proportion of anti-CCP positive patients in subgroups carrying two, one, or no SE alleles. anti-CCP, anti-cyclic citrullinated peptide antibody; CI, confidence interval; NS, not significant; OR, odds ratio; RF, rheumatoid factor; SEM, standard error of the mean.